Atlas Trials

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Clinical trial NCT02003209 · COMPLETED

Trial details

NCT number
NCT02003209
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
HER2-Positive Breast CarcinomaHormone Receptor-Positive Breast CarcinomaStage IB Breast Cancer AJCC v7Stage IIA Breast Cancer AJCC v6 and v7Stage IIB Breast Cancer AJCC v6 and v7Stage IIIA Breast Cancer AJCC v7Stage IIIB Breast Cancer AJCC v7Stage IIIC Breast Cancer AJCC v7
Start date
2014-02-18
Primary completion
2016-10-31
Enrollment
315

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.